Consensus Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-08 EDT			5-day change	1st Jan Change
2.36 ^USD	+9.26%		-7.09%	-26.27%

04-30	Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	CI
03-26	Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Virpax Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

209c33993290dd3f146b.0_u2E1DnDmqEBrSHcJdiv8Pbob6lAKASU8RmBw5JXl8.p4jiIBKNVF7SNMPfEcRX0amZ8NTwZJRhFv0hRV0IGQm61s9UJbA2Guw00w~94ca573fb702f73c998351fc6c0e9f32

Analyst Recommendations on Virpax Pharmaceuticals, Inc.

Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data	23-02-13	RE
Maxim Group Initiates Coverage on Virpax Pharmaceuticals With Buy Rating, $4 Price Target	22-06-09	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.36 USD

Average target price

20 USD

Spread / Average Target

+747.46%

High Price Target

20 USD

Spread / Highest target

+747.46%

Low Price Target

20 USD

Spread / Lowest Target

+747.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Virpax Pharmaceuticals, Inc.

Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar